We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MCRB Seres Therapeutics Inc

0.04 (3.77%)
Last Updated: 14:22:55
Delayed by 15 minutes


Draw Mode:

Volume 1,688,356
Bid Price 1.10
Ask Price 1.11
News -
Day High 1.145


52 Week Range


Day Low 1.0411
Share Name Share Symbol Market Stock Type
Seres Therapeutics Inc MCRB NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.04 3.77% 1.10 14:22:55
Open Price Low Price High Price Close Price Previous Close
1.09 1.0411 1.145 1.06
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
5,915 1,688,356 US$ 1.11 US$ 1,875,646 - 0.91 - 6.87
Last Trade Type Quantity Price Currency
14:22:55 100 US$ 1.10 USD

Seres Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
143.48M 129.26M - 7.13M -250.16M -1.94 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Seres Therapeutics News

Date Time Source News Article
11/28/202308:18Business WireSeres Therapeutics to Participate in the Piper Sandler 35th..
11/27/202318:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with..
11/21/202305:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create..
11/02/202309:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202306:05Edgar (US Regulatory)Form 8-K - Current report
11/02/202306:00Business WireSeres Therapeutics Reports Third Quarter 2023 Financial..
11/01/202309:30PR Newswire (US)Flagship Pioneering Launches Pioneering Intelligence
10/31/202320:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/31/202320:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/31/202320:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/31/202320:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/31/202320:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MCRB Message Board. Create One! See More Posts on MCRB Message Board See More Message Board Posts

Historical MCRB Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.151.200.981.082,798,587-0.05-4.35%
1 Month1.231.440.92071.083,204,118-0.13-10.57%
3 Months3.053.1850.911.493,669,335-1.95-63.93%
6 Months4.736.260.912.843,010,316-3.63-76.74%
1 Year6.436.870.913.852,444,485-5.33-82.89%
3 Years25.3529.900.917.261,630,655-24.25-95.66%
5 Years7.8638.500.919.231,255,517-6.76-86.01%

Seres Therapeutics Description

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |